Phase 2 Randomised Controlled Trial and Feasibility Study of Future Care Planning in Patients with Advanced Heart Disease

Martin A. Denvir, Sarah Cudmore, Gill Highet, Shirley Robertson, Lisa Donald, Jacqueline Stephen, Kristin Haga, Karen Hogg, Christopher J. Weir, Scott A. Murray, Kirsty Boyd

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Future Care Planning (FCP) rarely occurs in patients with heart disease until close to death by which time the potential benefits are lost. We assessed the feasibility, acceptability and tested a design of a randomised trial evaluating the impact of FCP in patients and carers. 50 patients hospitalised with acute heart failure or acute coronary syndrome and with predicted 12 month mortality risk of >20% were randomly allocated to FCP or usual care for 12 weeks upon dis-charge and then crossed-over for the next 12 weeks. Quality of life, symptoms and anxie-ty/distress were assessed by questionnaire. Hospitalisation and mortality events were docu-mented for 6 months post-discharge. FCP increased implementation and documentation of key decisions linked to end-of-life care. FCP did not increase anxiety/distress (Kessler score -E 16.7 (7.0) vs D 16.8 (7.3), p=0.94). Quality of life was unchanged (EQ5D: E 0.54(0.29) vs D 0.56(0.24), p=0.86) while unadjusted hospitalised nights was lower (E 8.6 (15.3) vs D 11.8 (17.1), p=0.01). Qualitative interviews indicated that FCP was highly valued by patients, car-ers and family physicians.FCP is feasible in a randomised clinical trial in patients with acute high risk cardiac condi-tions. A Phase 3 trial is needed urgently.
Original languageEnglish
Article number24619
JournalScientific Reports
Volume6
DOIs
Publication statusPublished - 19 Apr 2016

Fingerprint

Dive into the research topics of 'Phase 2 Randomised Controlled Trial and Feasibility Study of Future Care Planning in Patients with Advanced Heart Disease'. Together they form a unique fingerprint.

Cite this